By doing early screening, it’s possible for researchers to accelerate process development and move to commercial bsAb ...

Ordspono is a CD20xCD3 bispecific monoclonal antibody that facilitates T cell engagement for the targeted killing of ...

Stay updated on promising new treatments for Diffuse Large B-cell Lymphoma and B-cell acute lymphoblastic leukemia in this ...

Medigene announces KRAS G12V as first target for TCR-guided T cell engagers: Planegg, Germany Tuesday, December 10, 2024, 17:00 Hrs [IST] Medigene AG, an oncology platform company ...

Hans Lee, MD, MD Anderson Cancer Center, talks about recent advancements in multiple myeloma treatment pathways.

The regulatory and sales milestones could also bring Biosion another $900 million. The two assets are BSI-045B, a high affinity and high potency anti-TSLP monoclonal antibody, and BSI-502, a ...

a novel anti-TSLP monoclonal antibody, and BSI-502, a novel bispecific antibody that is directed against both TSLP and IL4R worldwide (excluding Greater China) Under the terms of the agreement ...

November 2024 has seen a variety of biotech deals take place to advance therapies across different stages in development.

Financially, Immunocore has a strong cash position and stable revenue growth, but concerns remain about the pipeline's ...

a novel anti-TSLP monoclonal antibody, and BSI-502, a novel bispecific antibody that is directed against both TSLP and IL4R worldwide (excluding Greater China) NEWARK, Del. and NANJING ...

Since the start of the year, Ipsen has bolstered its oncology pipeline with two ADC alliances – with Foreseen Bio and Sutro ...